Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given an average rating of “Hold” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.00.

Several equities research analysts recently issued reports on the stock. TD Cowen cut shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics in the 1st quarter valued at about $46,000. Engineers Gate Manager LP purchased a new position in Jasper Therapeutics in the second quarter valued at approximately $78,000. Panagora Asset Management Inc. purchased a new position in Jasper Therapeutics in the fourth quarter valued at approximately $35,000. Voleon Capital Management LP acquired a new position in Jasper Therapeutics during the third quarter valued at approximately $50,000. Finally, XTX Topco Ltd acquired a new position in Jasper Therapeutics during the second quarter valued at approximately $152,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Down 0.8%

Shares of NASDAQ:JSPR opened at $0.66 on Thursday. The company has a market cap of $18.48 million, a P/E ratio of -0.20 and a beta of 3.02. The business has a fifty day simple moving average of $0.57 and a 200-day simple moving average of $0.94. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $3.14.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.08. Sell-side analysts expect that Jasper Therapeutics will post -1.67 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.